For many patients with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) remain the treatment of choice, according to David Armstrong, MA, MB, BChir, FRCP (UK), FRCPC, FACG, AGAF, and colleagues. “However, despite PPI therapy, many patients with GERD continue to be symptomatic,” they write.
Trending
- State laws may be curbing private equity takeovers of physician group (STAT)
- AI Shows Promise Across Spectrum of GI Motility Diagnostics, Review Finds (GI & Endoscopy News)
- Simple mouth rinse may help detect stomach and colorectal cancer signals (Medical Xpress)
- Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs (MedCity News)
- Top AI in Endoscopy Companies Revolutionizing Real-Time Diagnostics and Intelligent Endoscopic Care (Fortune Business Insights)
- Rome V criteria capture more people with IBS, but a milder group (GI & Hepatology News)
- Real-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic Costs (Business Wire)
- FITs Offer Lowest Environmental Footprint Among CRC Screening Options (AJMC)
